Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $47.2 million.

  • Amphastar Pharmaceuticals' Free Cash Flow rose 230.89% to $47.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.3 million, marking a year-over-year decrease of 3343.97%. This contributed to the annual value of $172.3 million for FY2024, which is 1858.3% up from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Free Cash Flow stood at $47.2 million, which was up 230.89% from $25.0 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Free Cash Flow peaked at $63.1 million during Q2 2024, and registered a low of -$4.6 million during Q3 2021.
  • Over the past 5 years, Amphastar Pharmaceuticals' median Free Cash Flow value was $26.4 million (recorded in 2021), while the average stood at $28.9 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Free Cash Flow tumbled by 24641.06% in 2021 and then surged by 187993.79% in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Free Cash Flow (Quarter) stood at $33.6 million in 2021, then plummeted by 73.44% to $8.9 million in 2022, then skyrocketed by 61.75% to $14.4 million in 2023, then grew by 15.19% to $16.6 million in 2024, then skyrocketed by 184.33% to $47.2 million in 2025.
  • Its last three reported values are $47.2 million in Q3 2025, $25.0 million for Q2 2025, and $24.4 million during Q1 2025.